Gain Therapeutics Shares Are Trading Higher After the Company Announced He Presentation of a Poster That Details the Use of Its Magellan Drug Discovery Platform to Identify Allosteric Inhibitors Targeting Discoidin Domain Receptor 2.
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Gain Therapeutics to Present at Michael J. Fox Foundation's 16th Annual Parkinson's Disease Therapeutics Conference
Gain Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Gain Therapeutics Excels in Neurodegenerative Drug Trials
